Solid Tumors clinical trials
Showing 651–700 of 1,133 active trials. Describe your situation to see which ones look like a fit.
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
- Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
- A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
- A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
- Stereotactic Magnetic Resonance Guided Radiation Therapy
- A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
- DPTX3186 in Wnt Pathway Activated Solid Tumors
- A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- A Study of JNJ-87890387 for Advanced Solid Tumors
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- A Study of DM002 in Patients With Advanced Solid Tumors
- X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- SMP-3124LP in Adults With Advanced Solid Tumors
- A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
- Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
- A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
- A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- Psilocybin Therapy in Advanced Cancer
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
- FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- A Study of DM005 in Patients With Advanced Solid Tumors
- Evaluate the Safety and Clinical Activity of HH2853
- Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
- Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.